What is Shockwave Medical's business focus and history?
Shockwave Medical, founded in 2009 by Daniel Hawkins and Todd Brinton, is a medical device company based in Santa Clara, California. Specializing in Intravascular Lithotripsy (IVL) technology, it offers innovative solutions for treating calcified cardiovascular diseases. Acquired by Johnson & Johnson in May 2024 for $13.1 billion, Shockwave Medical continues to operate as a business unit within Johnson & Johnson MedTech, focusing on transforming patient care in cardiovascular health.
Shockwave Medical Corporate Details & Core Services
Shockwave Medical is a medical device company specializing in developing and commercializing Intravascular Lithotripsy (IVL) technology for the treatment of calcified cardiovascular diseases. Their innovative products aim to transform patient care by providing minimally invasive solutions for conditions such as coronary and peripheral artery diseases.
Shockwave Medical Contact Information & Official Links
Medical DevicesCardiovascular HealthIntravascular LithotripsyHealthcare Technology
What are Shockwave Medical's Key Business Metrics & Stats?
No of employees
1468
Founded year
2009
Type
private
Industry
Medical Devices
Location
Santa Clara, California, United States
Parent Company
jnjmedtech.com
How much funding has Shockwave Medical raised to date?
Name
Description
Funding Amount
USD 798 Million
Stage
Series Unknown
Latest Valuation
13.1 Billion (USD)
Investors
Deerfield, Fidelity, RA Capital Management, Sofinnova Partners, Venrock
What are Shockwave Medical's Core Products?
Name
Description
Shockwave C2+ Coronary IVL Catheter
An intravascular lithotripsy catheter designed for the treatment of calcified coronary artery disease, enhancing vessel preparation prior to stenting.
Shockwave L6 Peripheral IVL Catheter
A catheter developed to modify calcification in large peripheral vessels, including the iliac and common femoral arteries.
Shockwave Javelin Peripheral IVL Catheter
A forward intravascular lithotripsy platform designed to modify calcium and cross extremely narrowed vessels in patients with peripheral artery disease.
Shockwave E8 Peripheral IVL Catheter
An enhanced catheter aimed at optimizing the treatment of calcified femoro-popliteal and below-the-knee peripheral artery disease.
Reducer System
A device designed to provide relief to patients suffering from refractory angina by altering blood flow within the myocardium.
What are the latest developments at Shockwave Medical?
Date
Type
Description
May, 2024
Acquisition
Johnson & Johnson completed the acquisition of Shockwave Medical for $13.1 billion, enhancing its cardiovascular intervention portfolio.
March, 2025
Product Launch
Shockwave Medical announced the U.S. launch of the Shockwave Javelin Peripheral IVL Catheter, a novel platform for treating calcified peripheral artery disease.
November, 2024
Clinical Outcomes
Shockwave Medical unveiled first clinical outcomes of the Shockwave Javelin Peripheral IVL Catheter at VIVA 2024, demonstrating safety and efficacy.
What industry awards and recognitions has Shockwave Medical received?
Date
Type
Description
January, 2024
Recognition
Named one of Newsweek's 2024 America's Greenest Companies for innovative approaches to reducing environmental impact.
April, 2023
Award
Received the Edison Awards 2023 Gold for Novel Medical application, recognizing the coronary Intravascular Lithotripsy technology.
What are Shockwave Medical's official legal and registration details?
Name
Description
Legal Name
Shockwave Medical, Inc.
Cin number
GST number
Registration number
Who is in Shockwave Medical's executive leadership team?
Name
Designation
CEO
Isaac Zacharias
Chief Executive Officer
Doug Godshall
Where are Shockwave Medical's primary office locations?
City
Country
Santa Clara
United States
Paris
France
What are the current business signals and market intelligence for Shockwave Medical?
